Comparison · NCT02781792-sae
Arm 1: Temozolomide Morning vs Arm 2: Temozolomide Evening: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1: Temozolomide Morning vs Arm 2: Temozolomide Evening: serious adverse events. Trial comparisons, record NCT02781792-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02781792-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.273 | 0.132 | 0.482 | wilson | |
| Risk in group 2 | 0.25 | 0.112 | 0.469 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0227 | -0.238 | 0.273 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.393 | 3.03 | log | |
| Odds ratio, group 1 over group 2 | 1.13 | 0.283 | 4.47 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm 1: Temozolomide Morning than on Arm 2: Temozolomide Evening | 44 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1: Temozolomide Morning | -Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m\^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00). | 6 | 22 | EG000 |
| Group 2 | Arm 2: Temozolomide Evening | -Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00). | 5 | 20 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality was collected from start of treatment through completion of follow-up (median length of follow-up 568.5 days, full range 1-1134 days) Adverse events were collected from start of treatment through end of treatment visit (median length of treatment 6 cycles - each cycle is 28 days (full range 2-12 cycles).
Source ClinicalTrials.gov
Trial
- Title
- Temozolomide Chronotherapy for High Grade Glioma
- NCT number
- NCT02781792
- Phases
- PHASE2
- Conditions
- Glioma, Glioblastoma Multiforme
- Interventions
- Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
- Lead sponsor
- Washington University School of Medicine
- Results first posted
- 2025-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02781792?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02781792-sae